Generac secured a major long-term agreement with Amazon to provide backup generators for its data centers, supporting Amazon's expanding AI and cloud infrastructure. The deal could generate up to $8 billion in revenue for Generac over time, with initial deliveries worth about $2.4 billion scheduled for 2027 and 2028. The agreement also includes warrants allowing Amazon to purchase up to 1.69 million Generac shares, potentially boosting Generac's stock value. This partnership positions Generac as a key player in powering large-scale data centers amid growing demand for reliable AI infrastructure.
Generac's $8 billion deal with Amazon is the story's subject, here is Pluang's Industrials sector snapshot for context. Of 76 priced US Industrials stocks on Pluang, 64 rose and 8 fell today. Delta Air Lines was up 2.17% at USD 79.56 with 100% buy orders, United Airlines rose 2.16% to USD 108.60 with balanced buy/sell orders, and Southwest Airlines gained 2.15% to USD 39.99. Data as of Sep 17, 2026 19:02 WIB.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
